Heart failure (HF) is the end-stage of all heart disease and arguably constitutes the greatest unmet therapeutic need in cardiovascular medicine today. Classic epidemiological studies have established clinical risk factors for HF, but the cause remains poorly understood in many cases. Biochemical analyses of small case-control series and animal models have described a plethora of molecular characteristics of HF, but a single unifying pathogenic theory is lacking. Heart failure appears to result not only from cardiac overload or injury but also from a complex interplay among genetic, neurohormonal, metabolic, inflammatory, and other biochemical factors acting on the heart. Recent development of robust, highthroughput tools in molecular biology provides opportunity for deep molecular characterization of population- Smith has reported that he has no relationships relevant to the contents of this paper to disclose.
increasing HF prevalence (4) and increasing incidence in young adults in Western countries (5) . Improved preventive and therapeutic tools are thus urgently needed.
Epidemiology is the study of disease occurrence and determinants of disease in populations and the application of such knowledge to disease control. Classic prospective, population-based epidemiological cohorts were instrumental for identification of modifiable risk factors for coronary artery disease (CAD), including smoking, hyperlipidemia, hypertension, and diabetes mellitus (6) . Essentially the same risk factors have been associated with HF, consistent with a large subset of HF cases caused by CAD (7, 8) .
However, the predictive accuracy of conventional risk factors for HF incidence is modest (8) Thus, HF appears to result not only from cardiac overload or injury but also from a complex interplay among genetic, neurohormonal, metabolic, inflammatory, and other biochemical factors with individually modest effects acting on the heart. However, the pathophysiological role of many biochemical characteristics remains unclear, and a single unifying pathogenic theory is lacking (9) . In order to better understand the relevance of a particular molecular state in patients with HF, the distribution of such states in the general population also needs to be characterized.
In recent years, the development of reproducible, high-throughput tools for molecular profiling has paved the way for the burgeoning field of molecular epidemiology: the coupling of information on molecular states to population-level disease data. Thus, thousands of human samples can now rapidly be characterized for genome sequence, myocardial gene expression profiles and chromatin modifications, plasma composition of proteins and metabolites, and microbiomes (Central Illustration, Table 1 ), comprehensive molecular profiling approaches that are agnostic to previous knowledge.
This article describes the application of molecular epidemiology tools to HF. An overview of the molecular methods and tissue types used is provided, with particular emphasis on the genome, myocardium, plasma, and the microbiomes. Recent examples of such studies are described, along with expectations based on previous case-control studies.
STUDY DESIGN IN MOLECULAR EPIDEMIOLOGY OF HF
Prospective, population-based cohort study is the preferred study design for molecular epidemiology as previously described in detail (10) , although most studies in the HF field published to date are casecontrol studies. Population-based cohort designs offer several advantages over other analytic study designs in observational epidemiology such as casecontrol studies, including avoidance of selection bias, recall bias, and differential misclassification bias, and allow study of trajectories and of multiple endpoints. Such designs offer opportunities for both pathophysiological insight into mechanisms involved in disease development and for disease outcomes (in the inception cohort), facilitating both primordial risk prediction and prediction of outcomes in distinct disease subsets ( Table 2) . With regard to HF, the ideal population-based cohort study should have several characteristics. First, given the heterogeneous nature of HF, very large cohorts are needed to capture sufficient numbers of incident events for robust analysis of relevant disease subsets. Several very large cohorts are currently being collected for study of the molecular epidemiology of a wide range of chronic diseases, as exemplified by the Precision Medicine Initiative in the United States, which aims to recruit 1 million participants, and the U.K. Biobank, which has recruited 500,000 participants. As costs are significant for several assays with high analyte throughput, a powerful and often more feasible approach than assaying the entire cohort is comparison of incident cases with a population-representative subcohort in a case-cohort or nested case-control design (11) . Second, phenotypic characterization of participants should be uniform and detailed, including modern imaging modalities (echocardiography or cardiac magnetic resonance imaging) which is necessary for the HF diagnosis. Heart failure should be clearly defined, given the overlap with a multitude of comorbidities that present with similar symptoms (e.g., pulmonary disease, renal disease, thyroid disease, and anemia) and may modify the severity of HF (1). Information on 
established causes and mechanistic information, such as systolic and diastolic cardiac function, should also be obtained. Third, sampling of tissues for molecular profiling should be performed from as many of the relevant tissues as possible (Central Illustration).
A major impediment is the difficulty of obtaining heart tissue. Fourth, serial examinations for repeated sampling are needed for analysis of processes that are dynamic over time, such as for transcriptomics, proteomics, and metabolomics, whereas the genome may be assayed at a single timepoint. Tissue sampling should ideally also be performed at different stages of HF development, including in subjects with early signs of heart injury, myocardial remodeling, and those with overt HF.
The ideal cohort for HF based on all the requirements outlined above is not feasible to collect.
Instead, international collaborative research consortia have formed to improve sample sizes by bringing together multiple population-based cohorts for molecular epidemiology research, as exemplified in Table 3 . A major challenge for consortia is harmonization of HF phenotypes and molecular assays across cohorts. In genomics, imputation of genotypes from different array-based genotyping platforms to common reference panels has been a successful approach (12) , whereas centralized analysis offers advantages for gene expression and plasma profiling assays. The analysis and integration of the large, multidimensional datasets generated by molecular assays constitutes another challenge. To date, data analysis has largely focused on robust detection of individual disease-associated markers with linear effects on disease risk, which can be separated from stochastic noise in data by using strict significance thresholds to control for multiple testing burden. With accumulating numbers of such molecules identified, analysts will need to embrace more complex models such as machine learning algorithms (13) to make use of the information content of datasets into predictive, diagnostic, and prognostic tools and complete un- 
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Resequencing of the 1p36 locus and patch clamp ex- Table 2 . involved in formation of the mammary glands and calcium metabolism. Motivated by these initial successes in small studies with <3,000 cases, international collaborative consortia for GWAS have been formed for more well-powered genomic analyses: for example, the HERMES (Heart Failure Molecular Epidemiology for Therapeutic Targets) consortium included >30,000 cases and >600,000 controls from >40 population-based cohorts, clinical trials, and clinical case collections to focus on both HF incidence and outcomes in HF (manuscript in preparation).
Similarly, the GENIUS-CHD (GENetIcs of sUbSequent Coronary Heart Disease) consortium brings together data for nearly 250,000 subjects with CAD from >50 studies for HF and other outcomes (40) . 
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receptor-2 and that the agonist of this receptor With more well-powered cohorts such as HERMES, Mendelian randomization studies will become an increasingly powerful tool to nominate therapeutic and preventive strategies for HF.
MOLECULAR PROFILING OF THE HEART IN HF
Population-based cohorts with heart tissue would be particularly valuable, as information on dynamic molecular states in the heart may reflect causespecific mechanisms of heart injury, the cardiac response to damage, remodeling processes, response to therapy, and potential for recovery of function ( Table 2) . Some degree of recovery of systolic function is not uncommon with modern therapy, but the mechanisms are poorly understood (56, 57) . In principle, heart tissue can be accessed postmortem, from explanted hearts of heart transplant patients, or from small endomyocardial biopsies obtained through sequencing of >40 tissues from >400 subjects, with left ventricle and atrial appendage samples from >200 subjects (59) . Detailed information on the myocardial transcriptome, proteome and metabolome is emerging from these datasets.
MYOCARDIAL TRANSCRIPTOME AND PROTEOME.
Gene expression profiling in human heart tissue in Different chromatin states can now be assessed at high throughput using a range of methods ( Table 4) A recent metabolomics study based on MS in human heart tissue from DCM patients and nonfailing controls confirmed substantially lower levels of fatty acids in HF and of long-chain acylcarnitines, the primary
substrates for mitochondrial fatty acid oxidation. 
Levels of acetyl-coenzyme
MICROBIOMES IN HF
The human body is estimated to harbor at least as many microbial cells as human cells (99) . Recent years have seen the development of tools to study the microbiome at scale, such as high-throughput sequencing of the ribosomal subunit 16S rRNA, which is highly species-specific and subject to slow whether these efforts will bear fruit into improved therapies and precision medicine for HF. 
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